Changing the fate of cellular immunotherapy

Clinical-stage biopharmaceutical company Fate Therapeutics is creating first-in-class (re)programmed cellular immunotherapies for cancer and immune disorders. Preclinical and clinical development of the company’s product pipeline is driven by a determined pursuit of a new cell therapy paradigm and an expanding array of strategic partnerships to support its innovative mission

Like Comment
Page of
Go to the profile of Fate Therapeutics

Fate Therapeutics

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.

No comments yet.